VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 14, 2007) - Pyng Medical Corp. (TSX VENTURE:PYT) is launching its FAST1(TM) Intraosseous Infusion System into twelve Asian countries, including The People's Republic of China, and has retained Business Asia Consultants Inc. as its contract regional manager to establish and manage distribution. FAST1(TM) is the only intraosseous infusion device able to provide rapid sternal access and delivery of life saving fluids and drugs to the heart of critically injured patients in seconds.
"We are delighted by the opportunity to launch the FAST1(TM) Intraosseous Infusion System throughout Asia, The FAST1(TM) is a unique, innovative life saving device that compliments our other product lines," said Lawrence Kronick, President of Business Asia Consultants Inc.
Business Asia Consultants is an international sales, marketing and business development consulting company with extensive experience in the Pacific Rim and Latin America. They will be working closely with Pyng to register the company with all the required regulatory agencies across Asia including the SFDA (Chinese regulatory agency) for sales of FAST1(TM) into China.
About Pyng Medical Corp.
www.pyng.com
Pyng Medical Corp. is a world-leader in intraosseous infusion with its proprietary award-winning FAST1(TM) Intraosseous Infusion System. The FAST1(TM) is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.
David Christie
(604) 303-7964
Website: www.pyng.com
